High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients

American Journal of Cardiovascular Drugs

Volumn 10, Issue 1, 2010, Pages 29-35

  Tavassoli, Neda ^a,b   Voisin, Sophie ^c   Carrie, Didier ^c   Lapeyre Mestre, Maryse ^a,b   Galinier, Michel ^c   Montastruc, Jean Louis ^a,b   Pathak, Atul ^a,b,c  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c CHU RANGUEIL   (France)

Author keywords

Angioplasty; Clopidogrel, adverse reactions; Clopidogrel, therapeutic use; Drug resistance; Stent thrombosis, prevention

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANGIOTENSIN II ANTAGONIST; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; POTASSIUM CHANNEL BLOCKING AGENT; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; BLEEDING; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; CORONARY STENT; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN TISSUE; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK REDUCTION; STENT THROMBOSIS; THROMBOCYTE AGGREGATION; THROMBOSIS PREVENTION;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY THROMBOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; FRANCE; HEMORRHAGE; HOSPITALS, UNIVERSITY; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; REGRESSION ANALYSIS; RISK; STENTS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 77149139817     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11318260-000000000-00000     Document Type: Article

References (27)

1. Serruys PW, De Jaegere P, Kiemeneij F, et al. A comparison of balloonexpandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994; 331: 489-495
2. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994; 331: 496-501
3. Moliterno DJ, Campbell CL. Unraveling questions surrounding clopidogrel resistance and stent thrombosis: one less snag. J Am Coll Cardiol 2007; 49: 2318-2319
4. Mehta SR, Yusuf S, Peters RJ, et al., Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-533
5. Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007; 49: 2312-2317
6. Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the Prepare Post-Stenting Study. J Am Coll Cardiol 2005; 46: 1820-1826
7. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175
8. Ajzenberg N, Aubry P, Huisse MG, et al. Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a casecontrol study. J Am Coll Cardiol 2005; 45: 1753-1756
9. Geisler T, Langer H, Wydymus M, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006; 27: 2420-2425
10. Gurbel PA, Bliden KP, Samara W, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005; 46: 1827-1832
11. Snoep JD, Hovens MM, Eikenboom JC, et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007; 154: 221-231
12. Smith Jr SC, Feldman TE, Hirshfeld Jr JW, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 113: e166-286
13. Angiolillo DJ, Bernardo E, Palazuelos J, et al. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions: results of a randomized study. Thromb Haemost 2008; 99: 161-168
14. Von Beckerath N, Kastrati A, Wieczorek A, et al. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J 2007; 28: 1814-1819
15. Fontana P, Senouf D, Mach F. Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness. Thromb Res 2008; 121: 463-468
16. Angiolillo DJ, Shoemaker SB, Desai B, et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 2007; 115: 708-716
17. Lemesle G, Delhaye C, Sudre A, et al. Impact of high loading and maintenance dose of clopidogrel within the first 15 days after percutaneous coronary intervention on patient outcome. Am Heart J 2009; 157: 375-382
18. Ruland S. Safety of clopidogrel and aspirin for stroke prevention: implications of the CHARISMA trial. Drug Saf 2008; 31: 449-458
19. MacWalter RS, Shirley CP. A benefit-risk assessment of agents used in the secondary prevention of stroke. Drug Saf 2002; 25: 943-963
20. Société Française de Cardiologie (SFC). Utilisation des stents actifs. Consensus d'experts de la Socié té Française de Cardiologie [online]. Available from URL: http://www.cardio-sfc.org/recommandations/sfc. [Accessed 2009 May 20]
21. Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007; 356: 1020-1029
22. Cuisset T, Frere C, Quilici J, et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 2006; 48: 1339-1345
23. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 1998; 280: 1690-1691
24. Tavassoli N, Duchayne E, Sadaba B, et al. Detection and incidence of druginduced agranulocytosis in hospital: a prospective analysis from laboratory signals. Eur J Clin Pharmacol 2007; 63: 221-228
25. Cuisset T, Frere C, Quilici J, et al. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. Thromb Haemost 2007; 97: 282-287
26. Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of periinterventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48: 1742-1750
27. Bonello L, Paganelli F, Arpin-Bornet M, et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007; 5: 1630-1636